AgingResearch.NewsJoin free

Tenecteplase

Tenecteplase has been studied in 3 papers since 2022: 1 trial and 2 observational studies in people. The newest paper, Sep 2, 2025: “Brain Frailty and Functional Outcomes After Thrombolysis for Acute Ischemic Stroke”.

Intervention

3 papers study it3 findingsUpdated

MeSH

See all 3

“Type of thrombolytic agent (TNK versus alteplase) did not modify the association between age and primary clinical outcome (Pinteraction=0.22).”
Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT TrialStroke2025doi:10.1161/strokeaha.124.049512

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: trials about aging, of every trial that tests the drug for any use.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 2 independent labs in 1 country
  • 4 trials, none about aging
  • 1 of 3 findings with company ties
  • Human trial1
  • Humans2

Studies in people

1 study gave tenecteplase to people and measured what changed.

  • up: Improves functional outcomemedian 3 vs 4, acOR 2.70, 95% CI 1.23-5.94

    down: Decreases mortalityacOR 0.34, 95% CI 0.13-0.91

    Review of trials137 people pooled>80 years90 days

    Older adults; The oldest old; Patient cohorts

    Neurology, Jan 11, 2022

What did studies of Tenecteplase find?

3

Studies of Tenecteplase measured 3 outcomes; the most studied are age-associated primary clinical outcome (1 study), mortality (1) and functional outcome (1).

Age-associated primary clinical outcome

no changein humans1

1 study

  1. Tenecteplase has no effect on age-associated primary clinical outcome in humans (Pinteraction=0.22).

    “Type of thrombolytic agent (TNK versus alteplase) did not modify the association between age and primary clinical outcome (Pinteraction=0.22).”

    Human trialacute ischemic stroke across age groupsn = 1,577

    Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial

    Stroke

Mortality

downin humans1

1 study

  1. Tenecteplase decreases mortality in humans (acOR 0.34, 95% CI 0.13-0.91).

    “reduced mortality (acOR 0.34, 95% CI 0.13-0.91) vs 0.40 mg/kg.”

    Human trialvs 0.40 mg/kg0.25 mg/kg90 daysn = 137

    Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials

    Neurology

Functional outcome

upin humans1

1 study

  1. Tenecteplase improves functional outcome in humans (median 3 vs 4, acOR 2.70, 95% CI 1.23-5.94).

    “TNK 0.25 mg/kg was associated with improved 90-day mRS (median 3 vs 4, adjusted common odds ratio (acOR) 2.70, 95% CI 1.23-5.94) and reduced mortality (acOR 0.34, 95% CI 0.13-0.91) vs 0.40 mg/kg.”

    Human trialvs 0.40 mg/kg0.25 mg/kg90 daysn = 137

    Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials

    Neurology

Trial sponsors

Latest

Related